Sevelar Sevelamer Carbonate tablets

Sevelar Tablets Sachets

Sevelamer Carbonate 400 / 800 mg Tablets

SEVELAR contains Sevelamer Carbonate, a non-calcium, non-metal phosphate binder used to help control elevated serum phosphate levels, particularly in patients with Chronic Kidney Disease (CKD), including those undergoing dialysis.

COMPOSITION

  • Sevelamer Carbonate – 400 mg
  • Sevelamer Carbonate – 800 mg

MODE OF ACTION

Sevelamer (a polymeric compound) binds phosphate within the intestinal lumen, limiting absorption and decreasing serum phosphate concentrations without altering calcium, aluminum, or bicarbonate concentrations.

DOSAGE

Control of serum phosphorous: Patients not taking a phosphate binder: 800–1600 mg 3 times/day with meals; the initial dose may be based on serum phosphorus levels: >5.5 mg/dL to <7.5 mg/dL: 800 mg 3 times/day, ≥7.5 mg/dL to <9.0 mg/dL: 1200–1600 mg 3 times/day, ≥9.0 mg/dL: 1600 mg 3 times/day

Maintenance dose adjustment based on serum phosphorous concentration (goal range of 3.5–5.5 mg/dL; maximum dose studied was equivalent to 13 g/day [sevelamer hydrochloride] or 14 g/day [sevelamer carbonate]): >5.5 mg/dL: Increase by 400–800 mg per meal at 2-week intervals, 3.5–5.5 mg/dL: Maintain current dose, <3.5 mg/dL: Decrease by 400–800 mg per meal.

INDICATIONS

In Control of serum phosphorous & Hyperphosphatemia

STORAGE

Store at room temperature not exceeding 30ºC.